Demand for a COVID-19 treatment has soared alongside a surge in Delta variant infections. Monoclonal antibodies (mAbs) are being promoted by politicians, doctors, and local nonprofits as a means of preventing severe symptoms, hospitalization, and death, especially in areas experiencing high numbers of cases.
COVID-19 recovery made easy
One factor fueling the treatment’s popularity is its convenient delivery. Having been granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA), the drugs are government-subsidized, making them free to all eligible patients. What’s more, they can be easily administered via infusion or injection from almost anywhere, even one’s own home. “Real-world study suggests that when patients who are at high risk due to a range of comorbidities contract a mild or moderate case of COVID-19, this combination of monoclonal injections gives them a chance of a nonhospitalized recovery. In other words, they recover safely at home,” says Raymund Razonable, MD, a Mayo Clinic infectious diseases specialist and senior author of two recent mAb studies.
Maximizing the effectiveness of mAbs
How effective are mAbs? Recent studies show they can reduce hospitalization and death in high-risk patients by about 70%. For those living with other high-risk individuals, the treatment can lower their risk of infection by 80%.
Now, thanks to new FDA approval, one mAb, Regeneron, can also be used as a preventative – other mAbs are taken once a person tests positive for COVID-19, while Regeneron can be administered after potential exposure, before a positive result. In either case, timing is critical: mAbs work best if provided within ten days of symptoms; the earlier, the better.
Filling the demand for mAb infusions
As demand increases, states and health providers are ramping up production, ensuring plenty of medicine to go around. According to doctors, the most significant impediment to treatment is lack of awareness: most patients just don’t know mAbs exist or that they’re eligible for them.
This is because many people assume mAbs are only for “high-risk” individuals, but high-risk in the context of mAbs is a broad term. The category includes comorbidities most likely to result in a dangerous case of COVID-19, such as age, and moderate risk factors, such as being overweight. Roughly 70% of Americans can receive mAbs, and those in public health are praying they use them if needed.
To determine if you’re eligible for free, at-home treatment, reach out now.